PRNewsWire
21 May 2026, 19:45 UTC · 17w ago
Verdict
Headline takes no side. We score GRCE −1.00 across three claims — strongly bearish.
−1.00strongly bearish
More negative than 96% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
The FDA issued a Complete Response Letter (CRL) rejecting the New Drug Application for Grace Therapeutics' GTx-104 due to manufacturing deficiencies and toxicology risks.
So whatA CRL is a major regulatory setback that prevents a drug from reaching the market, directly impacting future revenue and company valuation.
More negative than 99% of claims this week
Pomerantz LLP is investigating Grace Therapeutics for potential securities fraud and unlawful business practices following the FDA's action.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More negative than 81% of claims this week
Grace Therapeutics' stock price fell approximately 45.48% to $2.35 per share immediately following the FDA announcement.
More negative than 66% of claims this week
Which stocks this story touches
More negative than 96% of ticker scores this week
The company received an FDA Complete Response Letter, suffered a 45% stock price crash, and is under investigation for securities fraud.
More negative than 87% of ticker scores this week
The company is being investigated by a law firm on behalf of investors regarding potential claims.
More negative than 87% of ticker scores this week
The company is being investigated by a law firm on behalf of investors regarding potential claims.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
2d ago
−3.2%
Price agrees with the score
$2.11 vs $2.18 close before publication (May 20) · not market-adjusted
GRCE chart →
